Manulife

FACT SHEET

MANULIFE DANA EKUITAS TEKNOLOGI KESEHATAN GLOBAL DOLAR

NOV 2023

Investment Objective

To achieve long term capital growth by investing mainly in equity securities of companies which predominant economic activities are in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology sectors, onshore and/or offshore, directly and/or through mutual fund(s).

| Fund Information | | |
|-------------------------|---|--------------------------------------|
| Inception Date | : | 18 Oct 21 |
| Inception Price | : | USD 1.0000 |
| Fund Size | : | USD 2,796,334.32 |
| Number of unit | : | 2,880,260.13 |
| Net Asset Value/Unit 3) | : | USD 0.9709 |
| Fund Currency | : | USD |
| Type of fund | : | Equity |
| Valuation | : | Daily |
| Custodian Bank | : | Bank DBS Indonesia |
| Annual Management Fee | : | 2.50% |
| Bloomberg Code | : | MATKGMU IJ |
| Fund Manager | : | PT Manulife Aset Manajemen Indonesia |
| | | |

| Risk classification is | based or | n type of fund. | | | | |
|------------------------|----------|-----------------|------|--------------|---|--------|
| Low | | | High | | | |
| | | | | | | |
| Money Market | Fixed | d Income | Bala | anced | | Equity |
| Allocation | | | | Portfolio | | |
| Equity | : | 80 - 100 % | | Equity | : | 99.69% |
| Money Market | : | 0 - 20 % | | Money Market | : | 0.31% |

Note

1) Annualized (1 year = 365 days) and using compound method (for products that have been more than one year old since inception).

2) The benchmark is MSCI World Health Care Index.

3) The Net Asset Value / Unit has calculated the costs, including fees related to transaction and transaction settlement as well as administration and recording.



Mutual Fund - BlackRock Global Funds - World Healthscience Fund



Fund Performance

| Performance in USD per (30/11/23) | | | | | | | | | Yearly Pe | rformanc | е | | | | | | |
|-----------------------------------|-------|--------|-------|--------|--------|--------------------|--------------------|-----------------------|------------------|----------|------|------|------|------|------|------|------|
| | 1 mo | 3 mo | 6 mo | YTD | 1 yr | 3 yr ¹⁾ | 5 yr ¹⁾ | Since Inception 1) | | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
| MANTKG | 3.96% | -4.43% | 0.14% | -3.43% | -3.40% | n/a | n/a | -1.38% | MANTKG | -4.60% | n/a |
| BM 2) | 5.73% | -1.91% | 1.73% | -0.64% | -1.82% | n/a | n/a | 0.64% | BM ²⁾ | -5.68% | n/a |



*Non Affiliates

Investment Manager Commentary

Global equity market rebounded in November supported by expectations that The Fed has reached peak rate which led to better market sentiment. Jower US Treasury vield, and weaker USD. The Fed held its rates steady at 5.25%-5.50% in the latest FOMC meeting and repeatedly delivering their message of being patient. Meanwhile, US economic data showed signs of slowing down that raises market expectation The Fed has reached its peak rate and potentially can pivot more accommodative in 2024. Cyclical and interest-rate sensitive sectors such as technology, real estate and financials outperformaned in the month as US Treasury yield came down and expectation that Fed rate has peaked. Amid market volatility we focus on stocks with attractive valuation, stable growth, and promising product pipelines. We also consider new innovations and technological developments for selective growth opportunities in the biotechnology, pharmaceuticals, and medical devices space.

Disclaimer: This report is prepared by PT Asuransi Jiwa Manulife Indonesia only for information purposes and not to be used as a sales offering or proposal. Although this report has been prepared meticulously, PT Asuransi Jiwa Manulife Indonesia does not guarantee its accuracy, sufficiency or completeness, and is not responsible for any consequences arising from any actions which are based on the information stated herein. Investments in capital market instruments are subject to various risks which include, but not limited to, market risk, credit risk, interest rate risk, exchange rate risk (particularly in Fund which has allocation in offshore investment instruments in different currencies than the Fund's currency), liquidity risk and other risks which could result in performance volatility. Therefore, the performance of this Fund is not guaranteed, the unit price of each Fund may go up or down and past performance does not necessarily indicative of future performance.

life Indonesia

rvices group that operates in Asia. Canada and the United Stat 11.000 emplo nsi Jiwa Manulife Indonesia are licensed and supervised by the Otoritas Jasa Keuangan (OJK). To learn more about Manulife Indonesia, follow us on Facebook, Twitter, Instagram, YouTube, or visi

(f) Manulife Indonesia () @Manulife_ID

() www.manulife.co.id

Top Holdings* & Sector Allocation

Manulife_ID Manulife Indonesia